Centre for the Commercialization of Antibodies

The Centre for the Commercialization of Antibodies (CCAB) is a Canadian non-profit organization focused on bridging the gap between academic discovery and the commercial development of antibody-based therapeutics and diagnostics. Based at the University of Toronto, CCAB leverages a high-throughput phage display platform to generate high-quality synthetic antibodies against a wide range of human targets. The center provides expertise in antibody engineering, validation, and scale-up to support academic researchers and industry partners. By facilitating the translation of intellectual property into clinical candidates, CCAB serves as a critical hub for the Canadian biotechnology ecosystem. It has successfully launched several spin-off companies and continues to provide specialized services for antibody discovery. Its collaborative model integrates academic innovation with industrial-scale development capabilities.